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Summary
 
Pathogenic effector T cells in experimental autoimmune uveitis (EAU) are T helper type 1–like,
 
and interleukin (IL)-12 is required for their generation and function. Therefore, we expected
that IL-12 administration would have disease-enhancing effects. Mice were immunized with a
uveitogenic regimen of the retinal antigen interphotoreceptor retinoid-binding protein, treated
with IL-12 (100 ng/d for 5 d), and EAU was assessed by histopathology. Unexpectedly, IL-12
treatment failed to enhance EAU in resistant strains and downregulated disease in susceptible
strains. Only treatment during the first, but not during the second, week after immunization
 
was consistently protective. High levels of interferon 
 
g
 
 (IFN-
 
g
 
) were present in the serum dur-
ing IL-12 treatment, but subsequent antigen-specific IFN-
 
g
 
 production in protected mice was
diminished, as were IL-5 production, lymph node cell proliferation, and serum antibody levels.
Treated mice had fewer cells and evidence of enhanced apoptosis in the draining lymph nodes.
Unlike wild-type mice, IFN-
 
g
 
–deficient, inducible nitric oxide synthase (iNOS)-deficient, and
 
Bcl-2
 
lck
 
 transgenic mice were poorly protected by IL-12, whereas IL-10–deficient mice were
protected. We conclude that administration of IL-12 aborts disease by curtailing development
of uveitogenic effector T cells. The data are compatible with the interpretation that IL-12 in-
duces systemic hyperinduction of IFN-
 
g
 
, causing activation of iNOS and production of NO,
which mediates protection at least in part by triggering Bcl-2 regulated apoptotic deletion of
the antigen-specific T cells as they are being primed.
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E
 
xperimental autoimmune uveitis (EAU)
 
1
 
 is an organ-
specific, T cell–mediated disease that is characterized
by inflammation and subsequent destruction of the neural
retina and related tissues, resulting in blindness. EAU can
be induced by immunization with one of several retinal an-
tigens in adjuvant in rodents and nonhuman primates, or
 
by adoptive transfer of retinal-specific CD4
 
1
 
 T cells be-
tween syngeneic rodents (1–4). The pathology of EAU in
the mouse model closely resembles that of human uveitic
diseases of putative autoimmune etiology (2). Therefore,
the study of immunological mechanisms affecting EAU can
help to understand human uveitis as well as other organ-
specific, T cell–mediated autoimmune diseases.
IL-12 is a heterodimeric protein composed of two disul-
fide-linked subunits of 40 kD (p40) and 35 kD (p35) (5, 6),
and is secreted predominantly from APCs in response to T
cell engagement of the MHC class II and CD40 molecules
(7, 8). Once secreted, IL-12 induces the release of IFN-
 
g
 
from NK cells and T cells and augments cell-mediated im-
mune responses in vitro and in vivo (9–15). IL-12 also reg-
ulates T cell–dependent immune responses by inducing
 
Some of the material in this manuscript was presented at the AAAAI/
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99[No. 5, Pt. 2]).
 
1
 
Abbreviations used in this paper:
 
 CIA, collagen-induced arthritis; DTH, de-
layed type hypersensitivity; EAE, experimental autoimmune encephalo-
 
myelitis; EAU, experimental autoimmune uveitis; GKO, IFN-
 
g
 
 knock-
out; iNOS, inducible nitric oxide synthase; IRBP, interphotoreceptor
retinoid-binding protein; KO, knockout; NO, nitric oxide; NOD, non-
obese diabetic; PTX, pertussis toxin. 
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differentiation toward the Th1 pathway (16, 17) and by
priming T cells for high IFN-
 
g
 
 production (18–20). Th1
cells characteristically produce IFN-
 
g
 
, lymphotoxin, and
IL-2, increase opsonizing antibody levels, and promote
cell-mediated immune reactions such as delayed hypersen-
sitivity. This is in contrast to Th2 cells, which produce IL-4,
IL-5, IL-10, and IL-13 and are involved in allergic re-
sponses (21).
We wished to investigate the effects of IL-12 on EAU
induction and expression. Results from our laboratory sug-
gest that the pathogenesis of EAU is associated with a Th1
response. Susceptible strains of mice and rats characteristi-
cally mount a Th1-dominated response to the uveitogen
and resistant strains do not (22, 23). Furthermore, IL-12 is
necessary to generate the functional uveitogenic effector T
cell (24). Because IL-12 promotes the differentiation of the
antigen-specific lymphocytes toward the Th1 pathway, we
hypothesized that potentiating the Th1 response might
overcome resistance in some nonsusceptible strains of mice.
Unexpectedly, IL-12 administration during the first week
after uveitogenic immunization consistently suppressed,
rather than exacerbated, EAU in all tested strains of mice.
This was accompanied by an overall reduction in immune
responsiveness to the immunizing uveitogenic antigen and
upregulation of apoptosis in the lymph nodes. Experiments
with gene knockout (KO) and transgenic mice supported
the interpretation that IL-12, through IFN-
 
g
 
–driven in-
duction of nitric oxide (NO), inhibits priming of antigen-
specific lymphocytes at least in part through Bcl-2–regu-
lated apoptosis, thus curtailing generation of uveitogenic
effector cells and resulting in protection from disease.
 
Materials and Methods
 
Mice.
 
C57Bl/6, BALB/c, A/J, AKR, DBA/1, and B10.BR
female mice were purchased from The Jackson Laboratory. Gene-
targeted stock was bred at the National Institutes of Health animal
facility. Mice with a targeted disruption of the IFN-
 
g
 
 gene (GKO)
were developed, screened, and back-crossed for eight generations
onto the C57Bl/6 background by Dalton et al. (25), and were ob-
tained from Genentech. Mice with a targeted disruption of the IL-
10 gene (10KO) were developed by W. Müller (Köln, Germany),
screened, and were back-crossed for eight generations onto the
C57Bl/6 background by Renate Morawetz (National Institute of
Allergy and Infectious Diseases). Inducible nitric oxide synthase–
deficient (iNOS KO) mice were bred from the original stock
developed by John MacMicking and Carl Nathan (Cornell Uni-
versity Medical College, New York) and John Mudgett (Merck
Research Laboratories, Rahway, NJ) (26). These mice are hybrids
of C57Bl/6 
 
3
 
 129. Wild-type C57Bl/6 
 
3
 
 129 control mice were
purchased from The Jackson Laboratory. Bcl-2 transgenic mice ex-
pressing human Bcl-2 under control of the 
 
lck
 
 promoter were bred
from the stock developed by the group of Korsmeyer and co-
workers (Washington University School of Medicine, St. Louis,
MO [27]) and were used as B6 
 
3
 
 C3H hybrids. Control mice of
the same genotype were purchased from The Jackson Laboratory.
All animals were housed under specific pathogen–free conditions,
were given water and chow ad libitum, and were used between
8 wk and 6 mo of age. The care and use of the animals was in
compliance with institutional guidelines.
 
Antigen and Reagents.
 
Interphotoreceptor retinoid-binding pro-
tein (IRBP) was isolated from bovine retinas by Con A–Seph-
arose affinity chromatography and fast performance liquid chro-
matography as described previously (28). Pertussis toxin (PTX)
and CFA were purchased from Sigma Chemical Co. 
 
Mycobac-
terium tuberculosis
 
 strain H37RA was purchased from Difco Labo-
ratories, Inc. Murine recombinant IL-12 was generously pro-
vided by M.K. Gately of Hoffman-LaRoche (Nutley, NJ).
 
Immunization and IL-12 Administration.
 
Mice were immunized
subcutaneously in the thighs and base of tail with 100–150 
 
m
 
g
IRBP in 0.2 ml emulsion 1:1 vol/vol with CFA containing 2.5
mg/ml 
 
M. tuberculosis.
 
 At the same time, mice were injected in-
traperitoneally with 1 
 
m
 
g PTX in 0.1 ml as an additional adju-
vant. In experiments with 10KO mice, the 
 
M. tuberculosis
 
 was de-
creased to 1 mg/ml, because higher concentrations of bacteria
increased fatalities, and the concentration of PTX was raised to
1.5–2.0 
 
m
 
g/mouse. IL-12–treated mice were injected intraperi-
toneally with graded doses of murine recombinant IL-12, as spec-
ified, for five consecutive days either early (days 0–4) or late (days
7–11) after immunization (day 0).
 
Histopathology and Scoring of EAU.
 
Whole eyes were collected
and prepared for histopathological evaluation at the termination of
an experiment (days 17–20 after immunization for 10KO experi-
ments or days 21–22 for all other experiments). The eyes were im-
mersed for 1 h in 4% phosphate-buffered glutaraldehyde and then
transferred into 10% phosphate-buffered formaldehyde until pro-
cessing. Fixed and dehydrated tissue was embedded in methacry-
late, and 4–6-
 
m
 
m sections were cut through the pupillary-optic
nerve plane. Sections were stained by hematoxylin and eosin. Pres-
ence or absence of disease was evaluated in a masked fashion by ex-
amining six sections cut at different levels for each eye. Severity of
EAU was scored on a scale of 0 (no disease) to 4 (maximum dis-
ease) in half-point increments, according to a semiquantitative sys-
tem described previously (29), which takes into account lesion
type, size, and number. In brief, the minimal criterion to score an
eye as positive by histopathology was inflammatory cell infiltration
of the ciliary body, choroid, or retina (EAU grade 0.5). Progres-
sively higher grades were assigned for presence of discrete lesions in
the tissue such as vasculitis, granuloma formation, retinal folding
and/or detachment, photoreceptor damage, etc.
 
Delayed Type Hypersensitivity.
 
2 d before the termination of
an experiment, mice received 10 
 
m
 
g of IRBP in 10 
 
m
 
l intrader-
mally into the pinna of one ear. The other ear was injected simi-
larly, but with PBS. Ear swelling was measured at the termination
of the experiment 48 h later with a spring-loaded micrometer.
Delayed type hypersensitivity (DTH) results are expressed as anti-
gen-specific swelling, calculated as the difference between the
thickness of the IRBP-injected ear and the PBS-injected ear.
 
Lymphocyte Proliferation.
 
Draining lymph nodes, the inguinals
and iliacs, were collected and pooled within each group at the
termination of an experiment (17–22 d after immunization).
Triplicate cultures of 5 
 
3
 
 10
 
5
 
 cells/well were stimulated with 30
 
m
 
g/ml IRBP in 96-well round-bottomed plates in RPMI sup-
plemented with 2-ME, glutamine, nonessential amino acids, so-
dium pyruvate, and antibiotics as described (1), 1% fresh-frozen
normal mouse serum, and 20 mg/ml 
 
a
 
-methyl mannopyranoside
(to neutralize any possible traces of Con A, which is used in the
initial stages of IRBP purification) (Sigma Chemical Co.). The
cultures were incubated for 60 h and were pulsed with [
 
3
 
H]thy-
midine (1.0 
 
m
 
Ci/10 
 
m
 
l per well) for the last 18 h.
 
Determination of Lymphokine Titers.
 
Draining lymph node cells
harvested 21 d after immunization were cultured as for the prolif-
eration assay above, except that double the number of cells per 
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well (10
 
6
 
) were stimulated with 50 
 
m
 
g/ml IRBP. Supernatants
were collected for cytokine analysis after 48 h. Blood for deter-
mination of IFN-
 
g
 
 serum titers was collected from the tail vein.
All samples were kept at 
 
2
 
70
 
8
 
C until being assayed. IFN-
 
g
 
, IL-4,
IL-5, IL-6, and IL-10 were measured by ELISA using antibody
pairs from PharMingen essentially as described previously (30).
ELISA detection kits from Endogen, Inc. were used to measure
TNF-
 
a
 
 and IL-10 in some experiments.
 
Detection of Apoptosis.
 
IRBP-immunized and naive mice
were treated with 100 ng/d of IL-12. Lymph nodes from treated
and untreated mice were collected on the specified days 24 h af-
ter the last IL-12 injection, and were fixed for 18 h in 10% neu-
tral buffered formalin. Fixed tissue was paraffin-embedded, sec-
tioned, and stained for apoptosis using the in situ TUNEL
staining kit from Oncor, Inc., as per the manufacturer’s instruc-
tions. TUNEL-positive cells were counted under the micro-
scope. Sections were scored in a blind fashion. For each lymph
node section, the entire section was scanned in consecutive fields,
and the average number of cells per field was calculated. Four to
seven sections originating from two to three draining lymph
nodes were evaluated per mouse.
 
Measurement of Antigen-specific IgG Antibody Isotypes.
 
Serum
levels of anti-IRBP IgG2a and IgG1 subclasses were determined
by ELISA in sera collected 21 d after immunization, as described
previously for another antigen (31). In brief, 96-well microtiter
plates (Costar Corp.) were coated with IRBP (1 
 
m
 
g/ml). After
blocking the plates with BSA (Sigma Chemical Co.) and an over-
night incubation with serum samples, the plates were developed
using horseradish peroxidase–conjugated goat anti-IgG subclass–
specific antibodies (PharMingen). The concentration of anti-
IRBP antibody was estimated using standard curves constructed
by coating wells with anti-Ig antibody and by adding polyclonal
Ig standards of the pertinent isotype.
 
Reproducibility and Statistical Analysis.
 
Experiments were re-
peated at least twice, and usually three or more times. Figures
show data compiled from several experiments, or from a represen-
tative experiment, as specified. Statistical analysis of EAU scores
was by Snedecor and Cochran’s test for linear trend in proportions
(nonparametric, frequency-based) (32). Each mouse (average of
both eyes) was treated as one statistical event. Antibody titers and
TUNEL staining data were analyzed using the independent 
 
t
 
 test.
Probability values of 
 
#
 
0.05 were considered significant.
 
Results
 
IL-12 Does Not Enhance EAU in Resistant Mouse Strains,
and Prevents EAU in Susceptible Strains.
 
We have shown
previously that susceptibility to EAU in rodents is associated
with a Th1-dominant response, whereas resistance is associ-
ated with Th1-low response to the uveitogenic antigen (22,
23). Therefore, we assumed that administration of IL-12
would enhance susceptibility in at least some EAU-resistant
mouse strains. Several mouse strains of different genetic
background and MHC, whose susceptibility to EAU was
characterized previously (23, 33), were injected with 100
ng/d of IL-12 for the first 5 d after immunization with
IRBP, as described in Materials and Methods. After IL-12
treatment, the resistant BALB/c strain remained resistant to
EAU. The moderately susceptible C57Bl/6 and minimally
susceptible DBA.1 were completely protected. The highly
susceptible B10.BR had strongly reduced disease scores (Ta-
ble I). In four subsequent experiments using the C57Bl/6
strain, it was determined that only early treatment (days 0–4
relative to immunization), but not late treatment (days
7–11), significantly decreased the incidence and severity of
EAU (
 
P
 
 
 
,
 
 0.006) (Fig. 1 A). Both incidence and severity of
disease in controls were typical of the C57Bl/6 strain, as seen
by us previously (33). In a series of experiments designed to
determine the dose–response of the protective effect, graded
doses of IL-12 (100, 10, and 1 ng/d) were administered on
days 0–4 (Fig. 1 B). A clear dose–response was apparent, in
which the protective effect titered out over two orders of
magnitude of IL-12 concentrations. None of the tested doses
resulted in an enhancement of disease scores.
 
IL-12 Administration Induces High Levels of Systemic IFN-
 
g
 
.
 
In a previous study, we noted that neutralization of sys-
temic IFN-
 
g
 
 in mice had an EAU-exacerbating effect, and
augmentation of systemic IFN-
 
g
 
 had a suppressive effect
(34). Because IL-12 induces IFN-
 
g
 
, we hypothesized that
the protective effect of IL-12 might be connected to a sys-
temic upregulation of IFN-
 
g
 
. Analysis of sera from IL-12–
treated mice showed that a single injection of 100 ng of
 
Table I.
 
IL-12 Administration Protects from EAU
 
Animal
BALB/c
(H-2
 
d
 
)
C57Bl/6
(H-2
 
b
 
)
DBA/1
(H-2
 
q
 
)
B10.BR
(H-2
 
k
 
)
IL-12 None IL-12 None IL-12 None IL-12 None
10
 
*
 
0 0 0.5 0 0 0.5 1.25
2 0 0 0 0.9 0 0.75 0.25 0.5
3 0 0 0 0.5 0 0.25 0.25 3
4 0 0 0 0.6 0 2 0 3
5 0 0 0 0.25 0 0 0.5 2.5
Average score 0 0 0 0.6 0 0.6 0.3 2.1
Incidence 0/5 0/5 0/5 5/5 0/5 3/5 4/5 5/5
 
*
 
EAU score (average of both eyes). 
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IL-12 was followed by an increase in serum IFN-
 
g
 
 that was
first detected at 9 h, and still remained elevated at 24 h (Fig.
2 A). Because IL-12 treatment was administered in the
EAU experiments every 24 h, IFN-
 
g
 
 serum titers of mice
treated with IL-12 would be expected to remain continu-
ously elevated throughout the 5-d treatment. This was sup-
ported by another series of experiments, where mice given
a uveitogenic immunization of IRBP were bled 12 h after
the first and the last IL-12 injections. IL-12–treated groups,
irrespective of the timing of the treatment (early versus
late), had nanogram quantities of IFN-
 
g
 
 in the serum,
whereas no IFN-
 
g
 
 could be detected in the serum of un-
treated controls (Fig. 2 B). A dose–response was apparent,
with mice treated with the highest dose of IL-12 showing
the highest serum IFN-
 
g
 
 titers (Fig. 2 C).
 
IL-12 Administration Does Not Protect IFN-
 
g
 
–deficient Mice
From EAU.
 
To test the hypothesis that elevated IFN-
 
g
 
serum titers were in fact connected to the protective effect
of IL-12, we used GKO mice on the C57Bl/6 background.
GKO mice and their wild-type littermates were given a
uveitogenic immunization of IRBP and were treated with
100 ng/d of IL-12 on days 0–4. IL-12 treatment did not
protect GKO mice from developing EAU, although it did
protect the wild-type littermates (
 
P
 
 
 
,
 
 0.009) (Fig. 3). The
incidence and severity of EAU in the GKO mice were
similar to our previous observations (35).
In addition to upregulating IFN-
 
g
 
, IL-12 has been re-
ported to upregulate IL-10 (20, 36). Because IL-10 has a
suppressive effect on EAU (30), it was necessary to address
the possibility that protection from EAU could at least in
part be due to upregulation of IL-10. Therefore, we treated
IRBP-immunized 10KO mice and their littermates with
100 ng/d of IL-12 on days 0–4 after immunization. Histo-
pathology of eyes collected 21 d later showed that IL-10–
deficient mice were protected equally to their wild-type
littermates, indicating that the protective effect of IL-12 is
independent of IL-10 (data not shown). Interestingly, the
10KO mice treated with IL-12 had four times as much cir-
culating IFN-
 
g
 
 as their wild-type littermates during treat-
ment (14.3 versus 3.6 ng/ml, respectively). This was in line
with the previously described suppressive effect of IL-10 on
IFN-
 
g
 
, an effect which is, of course, absent in 10KO mice
(37, 38).
 
Antigen-specific Production of Both IFN-
 
g
 
 and IL-5 Is Re-
duced in Mice Treated Early with IL-12.
 
Antigen-specific
IFN-
 
g
 
 production is considered indicative of the Th1 re-
sponse, whereas antigen-specific IL-4 and IL-5 production
can be used to assess the Th2 response. Mice were immu-
nized for EAU induction and were treated with the protec-
tive, or the nonprotective, IL-12 regimen. Draining lymph
node cells were collected on day 21 and were stimulated in
culture with IRBP. Supernatants were assayed for lym-
phokine content by ELISA as described in Materials and
Methods. The protected early treatment group, but not the
unprotected late treatment group, consistently had strongly
decreased production of IFN-
 
g
 
 to IRBP in culture, which
showed a clear dose–response (Fig. 4, A and B). The same
mice also showed reduced IRBP-specific production of IL-5,
Figure 1. C57Bl/6 mice are protected from EAU by IL-12 adminis-
tered early, but not late, after immunization. C57Bl/6 mice were immu-
nized with IRBP on day 0 and were treated (or not) with recombinant
murine IL-12, as indicated. (A) Timing of treatment: after immunization,
mice were given daily injections of 100 ng of IL-12 early (days 0–4), late
(days 7–11), or were left untreated (None). (B) Dose–response. On days
0–4 after immunization mice were given daily injections of graded doses
of IL-12; high dose (100 ng), intermediate (10 ng), or low dose (1 ng), or
were left untreated (None). Eyes were harvested for histopathology on
days 21–22 and were graded on a scale of 0 (no disease) to 4 (maximal
disease) in half-point increments. Each point is one mouse (average of
both eyes). The average of each group is denoted by a horizontal bar. The
data are compiled from six experiments (A), and three experiments (B).
Figure 2. Systemic produc-
tion of IFN-g under IL-12 treat-
ment. (A) After a single injection
of IL-12. Naive C57Bl/6 mice
were injected with 100 ng of
IL-12 at 0 h. Serum was collected
at the indicated times after IL-12
injection and serum IFN-g was
measured by specific ELISA. (B)
Timing. Mice received 100 ng
IL-12 injections early (days 0–4)
or late (days 7–10) or were left
untreated (None). (C) Dose–
response. On days 0–4 after im-
munization mice received graded
doses of IL-12; high dose (100
ng/d), intermediate dose (10 ng/
d), low dose (1 ng/d), or were left untreated (None). Blood was collected from the tail vein 12 h after their first and last IL-12 injections. The sera were
pooled within each group (three to six mice) and were analyzed for IFN-g by ELISA.223 Tarrant et al.
albeit to a somewhat lesser extent than of IFN-g. Again, a
dose–response was apparent (Fig. 4, C and D). Antigen-
specific TNF-a and IL-10 production did not differ signif-
icantly between the two IL-12 treatment groups and un-
treated controls, and IL-4 was not detectable by ELISA in
any of the supernatants (data not shown).
IL-12 Treatment Decreases Antigen-specific DTH and Anti-
gen-specific Proliferation. 19 d after uveitogenic immuniza-
tion IL-12–treated and control C57Bl/6 mice were chal-
lenged for DTH response by ear assay. 48 h later the ear
swelling was measured and specific DTH responses were
calculated. IL-12–treated mice had decreased DTH re-
sponses, with the early treatment group having the lowest
scores (P vs. untreated , 0.003) (Fig. 5). The reduction of
scores in the late treatment group was not significantly dif-
ferent from control (P , 0.13). Statistical significance not-
withstanding, the strong reduction of disease scores con-
trasts with the milder reduction of DTH. This is observed
consistently in our experiments with whole bovine IRBP
as immunogen. While disease is, by definition, a manifesta-
tion of the response to the conserved autologous epitopes,
DTH represents the sum of the response to autologous and
to immunodominant foreign epitopes. The more restricted
self-reactive repertoire may be easier to inhibit than the
stronger response to the xenogeneic epitopes, which can
explain the more dramatic effect on disease than on DTH.
Draining lymph nodes of IRBP-immunized, IL-12–
treated mice were cultured with IRBP. Lymph node cells
of mice that received early IL-12 treatment exhibited a
suppression of IRBP-specific proliferation, which was clearly
dose–dependent (Fig. 6, A and B). In contrast, lymph node
cell proliferation of GKO mice was much less amenable to
inhibition by early IL-12 treatment, in keeping with their
lack of protection from EAU. In a representative experi-
ment, proliferation of wild-type lymph node cells was re-
duced by half (from 122,000 to 63,000 cpm), whereas pro-
liferation of GKO cells was reduced by only 12% (from
207,000 to 181,000 cpm).
Anti-IRBP Antibody Response of IL-12–treated Mice.
C57Bl/6 mice were immunized with 100 mg of IRBP, and
were given either timed treatment of 100 ng IL-12, or an
early treatment with graded doses of IL-12. Sera were col-
lected from individual mice 21 d after immunization and
were analyzed for IRBP-specific antibody production as
described in Materials and Methods. In mice treated with
an early regimen of high-dose IL-12 the IgG2a/IgG1 ratio
was reversed, reminiscent of a Th1-dependent isotype
switch (Table II). However, at the same time, these mice
showed evidence of immune suppression, in that they had
the lowest combined IgG antibody level (IgG1 1 IgG2a)
(P versus untreated , 0.003). The extent of suppression in
Figure 3. IL-12 treatment
fails to protect IFN-g–deficient
mice from EAU. Mice were
immunized with IRBP on day 0
and received daily injections of
100 ng of IL-12 (days 0–4) or
were left untreated (None).
Eyes for EAU evaluation were
harvested for histopathology on
day 21 and were graded on a
scale of 0 (no disease) to 4
(maximal disease) in half-point
increments. Each point is one
mouse (average of both eyes).
The average of each group is denoted by a horizontal bar. Data are
compiled from three experiments.
Figure 4. Antigen-specific production of IFN-g (A and B) and IL-5 (C
and D) in mice treated with IL-12. (A) Timing. IFN-g production after
injections of IL-12 early (days 0–4) or late (days 7–11) or untreated
(None). (B) Dose–response. IFN-g production after administration of
graded doses of IL-12 on days 0–4. (C) Timing. IL-5 production by the
mice described in A. (D) Dose–response. IL-5 production by the mice
described in B. Draining lymph node cells were collected on day 21 and
were pooled within each group. Cultures were stimulated with IRBP (50
mg/ml) and supernatants collected at 48 h were assayed by ELISA. Data
represent an average of four experiments, each normalized to its control
group to compensate for interexperiment variation. Shown is the per-
centage of response relative to control 6 standard deviation.
Figure 5. DTH is reduced in
IL-12–treated mice. Mice re-
ceived intradermal injections of
10 mg IRBP in one ear and PBS
in the other ear 2 d before the
termination of an experiment.
After 48 h, ear swelling was
measured. DTH results are ex-
pressed as antigen-specific swell-
ing, calculated as the difference
between the thickness of the
IRBP-injected ear and the PBS-
injected ear. Each point of the
graph represents an individual mouse. The data are compiled from four
experiments. The means are shown as horizontal bars.224 IL-12 Protects from Experimental Autoimmune Uveitis
IgG Ab level was dependent on IL-12 timing and dose, and
generally correlated with protection from disease.
IL-12–treated Mice Have a Reduced Yield of Cells, and an
Enhanced Number of TUNEL-positive Cells, in the Draining
Lymph Nodes. After observing that IL-12–treated mice
had decreased antigen-specific in vitro proliferation, de-
creased DTH, and reduced lymphokine production, we in-
vestigated the possibility that IRBP-specific cells were be-
ing deleted in the lymph node during the priming of the
immune response. Total cell counts from the draining
lymph nodes were obtained at the termination of an exper-
iment, and mice that had received IL-12 early had up to a
50% reduction in cell number compared to untreated con-
trols (Fig. 7). To test the hypothesis that the decreased cell
number was a result of IL-12–induced programmed cell
death, lymph nodes obtained from IL-12–treated and un-
treated mice were extracted 24 h after a consecutive IL-12
treatment, and were sectioned and stained for apoptosis by
the TUNEL method. The count and the distribution of
TUNEL-positive cells in individual tissue sections were
highly variable, necessitating evaluation of the entire sec-
tion area in up to seven sections for each mouse. The num-
ber of TUNEL-positive cells in draining lymph nodes of
IRBP-immunized mice showed a modest increase as a re-
sult of immunization alone, and was upregulated by the IL-12
treatment in a time-dependent fashion (Fig. 8). Unimmu-
nized mice treated with IL-12 also had evidence of in-
creased apoptosis in peripheral lymph nodes, as did immu-
nized mice treated with IL-12 during the second week
after immunization, that were not protected. In contrast,
GKO mice appeared to develop fewer TUNEL-positive
cells in the draining lymph nodes than did the wild-type
mice as a result of IL-12 treatment. Furthermore, even with-
out IL-12 treatment, their background levels of TUNEL-
positive cells were low compared to wild-type mice (data
not shown).
iNOS KO Mice Have a Reduced Ability to Be Protected from
EAU by IL-12 Treatment. IFN-g is a major inducer of
iNOS, and consequently of NO, which can trigger pro-
grammed cell death. Therefore, it was of interest to exam-
ine a possible connection between induction of iNOS and
protection from EAU. To address this question, iNOS KO
mice were immunized for induction of EAU and were
treated with an early regimen of IL-12. The results showed
that while EAU in wild-type mice was strongly suppressed,
iNOS KO mice were not well protected by IL-12 treat-
ment (Fig. 9 A). Whereas there was no statistically signifi-
cant difference in disease scores between iNOS KO and
wild-type mice that did not receive IL-12 (P  5 0.74),
scores of IL-12–treated iNOS KO and IL-12–treated wild-
type mice differed at the highly significant probability value
of P , 0.005. In keeping with the reduced protection, an-
tigen-specific proliferation of lymph node cells from iNOS
KO mice was not as effectively suppressed by IL-12 treat-
ment as in the wild-type mouse (Fig. 9 B). TUNEL stain-
ing of lymph nodes from these mice confirmed that after 4 d
of treatment with IL-12 the wild-type animals had more
evidence of apoptosis, although the difference did not
achieve statistical significance (P , 0.1). This may stem
from the incomplete effect of IL-12 treatment in this strain,
Figure 6. IRBP-specific in
vitro proliferation is reduced in
lymph node cultures of IL-12–
treated mice. (A) Timing.
C57Bl/6 mice received a high
dose of IL-12 (100 ng/d) either
early (days 0–4) or late (days 7–
11) after immunization with
IRBP. (B) Dose–response.
C57Bl/6 mice received a high
dose (100 ng/d), intermediate
dose (10 ng/d), or low dose
(1 ng/d) of IL-12 on days 0–4
after immunization with IRBP.
Draining lymph node cells were
collected 21 d after immuniza-
tion and were pooled within
each group. Triplicate cultures
were stimulated with IRBP (30
mg/ml). Proliferation of each
group is shown as percent re-
sponse relative to the control
group, after background subtrac-
tion. Each point represents one
experiment. The means are
shown as horizontal bars.
Table II. Protective Administration of IL-12 Reverses the Isotype 
Ratios But Suppresses Total Antibody Levels
IL-12
treatment
Amount of
IL-12 IgG1 IgG2a
IgG1/IgG2a
ratio
Number
of samples
(ng) (mg/ml)* (mg/ml)*
Early 100 8,476 19,747 2.33 20
10 166,958 14,753 0.09 8
1 275,749 2,436 0.01 12
Late 100 43,081 6,317 0.15 11
None 210,483 4,089 0.02 18
*Calculated by averaging the titers of individually assayed serum samples.
Figure 7. Mice treated early
with IL-12 have decreased num-
bers of cells from the draining
lymph nodes. C57Bl/6 mice re-
ceived a high dose of IL-12 (100
ng/d) either early (days 0–4) or
late (days 7–11) after immuniza-
tion with IRBP. Draining lymph
node cells (iliacs and inguinals)
were collected, pooled, and
counted within each group at the
termination of an experiment.
Each point of the graph is a sepa-
rate experiment (average number
of lymph node cells per mouse in
a group of five mice). The means
are shown as horizontal bars.225 Tarrant et al.
combined with the inherent limitations of TUNEL in tis-
sue sections as a quantitative assay.
Bcl-2 Transgenic Mice Have a Reduced Ability to be Protected
by IL-12 Treatment. NO-induced apoptosis is known to
involve downregulation of the antiapoptotic protein Bcl-2,
and forced expression of Bcl-2 counteracts NO-induced
apoptosis (39–42). To test whether Bcl-2 overexpression
could counteract IL-12–induced protection from EAU, we
used mice transgenic for human Bcl-2 on the lck promoter,
which overexpress Bcl-2 in their T lymphocytes (27). Bcl-2
transgenic and wild-type mice were treated with an early
regimen of IL-12 after uveitogenic immunization. As with
other strains, disease in the wild-type mice was essentially
completely prevented by IL-12: only 2 mice of 11 devel-
oped minimal disease, and 1 of the 2 was affected in only
one eye. In contrast, Bcl-2 transgenic mice were deficient
in developing protection; 9 of 11 Bcl-2 transgenic mice
treated with IL-12 developed bilateral EAU, albeit with
lower scores than did untreated Bcl-2 transgenic animals
(Fig. 10 A). The difference in disease scores between IL-12–
treated wild-type and IL-12–treated Bcl-2 transgenic mice
was highly statistically significant at P , 0.008. In keeping
with their reduced protection from EAU, lymphocyte pro-
liferation to IRBP of Bcl-2 transgenic mice was consider-
ably less suppressed by IL-12 than that of wild-type mice
(Fig. 10 B). DTH responses exhibited the same pattern (not
shown). TUNEL staining of lymph nodes from IL-12–
treated Bcl-2 transgenic mice revealed the presence of
some apoptotic cells, although in reduced numbers com-
pared with wild-type mice.
Discussion
The assumption that led to the present study was that if a
Th1-low response underlies resistance to EAU, then treat-
ment with IL-12 should upregulate disease. In view of the
numerous published reports showing exacerbating effects
of IL-12 treatment on cell-mediated autoimmunity (43–
46), the unequivocal protection seen in the present study
was surprising. However, it was reminiscent of previously
reported protective effects of systemic IFN-g in both EAU
Figure 8. IL-12 treatment induces apoptosis in the draining lymph
nodes. C57Bl/6 mice immunized with IRBP received 100 ng IL-12/d
for 5 d after immunization. Lymph nodes were collected, fixed, and par-
affin-embedded 1, 2, or 4 d after immunization, 24 h after the preceding
IL-12 injection (one, two, or four treatments, respectively). TUNEL
staining of tissue sections was performed as described in Materials and
Methods. (A) Mean number of TUNEL-positive cells per field at each
time point 6 standard deviation. The value at time 5 0 is naive mice.
The data are a composite of two experiments, and represent a total of 66
lymph node sections derived from 15 mice (2–4 mice per time point). (B)
Photomicrograph of draining lymph nodes from an IL-12–treated (day 4)
or untreated mouse. Note numerous TUNEL-positive cells in the treated
mouse (3400).
Figure 9. iNOS KO mice have
reduced protection from disease
and reduced inhibition of lym-
phocyte proliferation in response
to IL-12 treatment. C57Bl/6 3
129 iNOS KO mice and matched
wild-type (WT) controls were im-
munized with IRBP on day 0 and
received daily injections of 100 ng
of IL-12 (days 0–4) or were left
untreated (None). (A) Eyes were
harvested for histopathology on
day 21 and were graded on a scale
of 0 (no disease) to 4 (maximal
disease) in half-point increments.
Each point is one mouse (average
of both eyes). The average of each
group is denoted by a horizontal
bar. The data are a composite of
three experiments. (B) Prolifera-
tion of lymph node cells to IRBP
in culture in counts per min (cpm)
was assayed as described in Mate-
rials and Methods. Background
counts ranged from 1.5 3 103 to
4 3 103 cpm.226 IL-12 Protects from Experimental Autoimmune Uveitis
and in experimental autoimmune encephalomyelitis (EAE)
(34, 47). Because IL-12 induces a strong systemic IFN-g
response (16), we hypothesized that suppression of EAU
might be related to an IL-12–induced elevation of systemic
IFN-g. Indeed, IL-12–treated mice exhibited nanogram
amounts of circulating IFN-g in the serum, whereas IFN-g
was undetectable in sera of untreated controls. The hy-
pothesis that IFN-g induction underlies the protective ef-
fect of IL-12 in the EAU model was borne out by the find-
ing that IFN-g–deficient mice could not be protected from
EAU by treatment with the same regimen of IL-12 that
was protective in wild-type mice. Although our experi-
ments do not identify the cellular source of this IFN-g,
data published by others suggest that it is likely to be de-
rived largely from NK cells and constitutes an antigen-
independent effect (16).
While the protective early IL-12 administration elevated
IFN-g in the serum during treatment, it strongly inhibited
the subsequent antigen-specific IFN-g production by lymph
node cells, indicating a suppressed Th1 response. This was
not only contrary to expectation, but also in apparent con-
tradiction to the observed shift towards IgG2a antibody
isotype in sera of the protected mice. However, in view of
the depressed overall IgG antibody response in these ani-
mals, we believe that this isotype shift was simply due to
the presence of excessive systemic levels of IFN-g (a switch
factor to IgG2a) at the appropriate time during evolution of
the antibody response, and not to enhanced Th1 help.
Because IL-12 in the human system has been shown to
induce IL-10, a cytokine that suppresses IFN-g production
and inhibits the Th1 response (20, 36), and because treat-
ment with IL-10 inhibits EAU (48), it was necessary to ad-
dress the possibility that the protective effect of IL-12 may
at least in part be due to induction of IL-10. The finding
that antigen-driven IL-10 production in the protected mice
was not affected did not tend to support this possibility.
More importantly, IL-10–deficient mice were protected
from disease equally to the wild-type mice, indicating that
the protective effect of IL-12 in this system is independent
of IL-10.
We next attempted to elucidate the mechanism by
which systemic IFN-g upregulation might mediate protec-
tion. The data showed that reduction of antigen-specific
responses in the protected mice was not restricted to Th1
(IFN-g). IL-5, a lymphokine produced by Th2 cells, as
well as lymphocyte proliferation and DTH were also sup-
pressed. This, together with a consistently reduced number
of cells in the draining lymph nodes, raised the possibility
that a deletion of IRBP-specific cells may be occurring. In
keeping with this, TUNEL staining of lymph nodes from
IL-12–treated mice showed increased numbers of apoptotic
cells and led us to postulate that the systemic hyperinduc-
tion of IFN-g caused by treatment with IL-12 protects
from EAU by causing programmed death of IRBP-specific
effector cells. This interpretation was further supported by
the finding that upregulation of TUNEL-positive cells in
IL-12–treated GKO mice, which were not protected, was
lower and not as consistent as in wild-type mice. An obser-
vation unconnected to the IL-12 treatment was that, while
in wild-type mice immunization alone increased the num-
ber of TUNEL-positive cells, that increase was minimal in
GKO mice. This last observation suggests that programmed
(activation-induced?) cell death in the draining lymph node
is at least in part dependent on IFN-g, and as a corollary,
that the enhanced proliferative responses that we and others
have noted in IFN-g–deficient and IFN-g receptor–defi-
cient mice (35, 49) may be related to a failure of IFN-g–
driven elimination of antigen-specific cells.
We next asked the question, what might be the mecha-
nism(s) downstream of IFN-g that could result in apopto-
sis? IFN-g is known to have antiproliferative effects on
many cell types, and at least some of those effects might be
connected to induction of cell death. IFN-g strongly up-
regulates iNOS, and consequently NO, which can cause
apoptosis, inhibition of lymphocyte growth, and downreg-
ulation of Th1 and Th2 cytokines (50–52). Other apopto-
sis-triggering molecules induced by IFN-g include TNF-a
and Fas (53–56). Finally, IFN-g has been implicated in
some studies as being able to directly induce apoptosis (57–
60). Because our previous work showed that GKO mice
immunized with a uveitogenic regimen of IRBP do not
upregulate iNOS (35), involvement of NO in protection
from EAU was immediately suspected. In keeping with this
hypothesis, IL-12–treated iNOS KO mice proved to be
deficient in their ability to be protected from EAU and
showed less suppression of their proliferative response to
IRBP than the wild-type mice. The present results are in
line with recent reports showing that inhibition of iNOS,
or disruption of its gene, exacerbate EAE and enhance
lymphocyte proliferation and IFN-g production (61, 62).
Figure 10. Bcl-2 transgenic
mice have reduced protection
from disease and reduced inhibi-
tion of lymphocyte proliferation
in response to IL-12 treatment.
C57BL/6 3 C3H Bcl-2 trans-
genic (TG) mice and matched
wild-type (WT) controls were im-
munized with IRBP on day 0
and received daily injections of
100 ng of IL-12 (days 0–4) or
were left untreated (None). (A)
Eyes were harvested for histopa-
thology on day 21 and were
graded on a scale of 0 (no disease)
to 4 (maximal disease) in half-
point increments. Each point is
one mouse (average of both
eyes). The data are a composite
of two experiments. The mean
score of each group is denoted by
a horizontal bar. (B) Proliferation
of lymph node cells to IRBP in
culture in counts per min (cpm)
was assayed as described in Mate-
rials and Methods. Background
counts ranged from 0.5 3 103 to
1.5 3 103 cpm.227 Tarrant et al.
Taken together with these reports, our data support the in-
terpretation that induction of NO is a major pathway
through which upregulation of IFN-g protects from au-
toimmune disease by curtailing the priming of autoaggres-
sive cells. Our data also point to NO-induced apoptosis as a
likely mechanism underlying the protective effects of sys-
temic IFN-g, that were repeatedly documented in Th1-
dependent autoimmune diseases such as EAU and EAE,
but were not adequately understood (34, 47, 49, 63).
NO-driven apoptosis is known to involve downregula-
tion of the Bcl-2 gene product, and forced expression of
Bcl-2 protects from NO-induced apoptosis (39–42). The
finding that mice transgenic for Bcl-2 under control of the
lck promoter were significantly deficient in developing pro-
tection from EAU after IL-12 treatment provides strong
evidence that protection is due at least in part to apoptotic
death of uveitogenic lymphocytes through the NO/Bcl-2
pathway. It should be noted, however, that the defect in
developing protection, which was very clear in GKO mice,
was not as complete in the iNOS knockouts and was partial
in the Bcl-2 transgenic mice. Since TUNEL-positive cells
were still evident in lymph nodes of Bcl-2 transgenic mice,
overexpression of the Bcl-2 transgene either did not com-
pletely prevent NO-induced T cell apoptosis, or alterna-
tively may indicate participation of other IFN-g–driven
apoptotic effects. Although experiments not shown here
have so far failed to implicate in a major way either Fas/FasL
or TNF-a–mediated apoptosis in the protection, they did
not exclude them. The present data also do not exclude
participation of nonapoptotic effects, such as inhibition of
proliferation or induction of anergy. In addition, the some-
what more moderate suppression of antigen-specific pro-
duction of IL-5 than of IFN-g after IL-12 treatment could
be indicative of a shift in the residual response towards a
less pathogenic phenotype. Lastly, although our results
strongly implicate apoptosis as a major mechanism in the
protection, a T cell receptor–transgenic system amenable to
clonotypic analysis is needed to demonstrate directly that
antigen-specific lymphocytes are among the cells undergo-
ing apoptosis. These questions will be the subject of a sepa-
rate study.
The protective effect of IL-12 was a time-limited phe-
nomenon, in that delayed IL-12 treatment was not protec-
tive despite the fact that it did elevate systemic IFN-g. This
suggested that the uveitogenic T cells are sensitive to elim-
ination only during the initial phase of their differentiation,
as they are being primed, but not later, when they have
already become mature effector cells. Two observations
showing a dissociation between protection and apoptosis
are in apparent contradiction to this interpretation, and
need to be reconciled: (a) lymph nodes of naive IL-12–
treated animals had increased numbers of apoptotic cells.
The answer to this is that naive mice are in fact constantly
being primed by environmental antigens; and (b) mice re-
ceiving the delayed (nonprotective) IL-12 treatment had
enhanced apoptosis in the draining lymph nodes. This is
explained by the fact that during the second week new cells
are continuing to be primed in the lymph node. While IL-12
treatment may be eliminating those, enough mature effec-
tors have already been generated to induce disease. Finally,
cells other than lymphocytes are likely to be undergoing
apoptosis as well, resulting in a background of TUNEL-
positive cells that is unrelated to an antigen-specific re-
sponse occurring in the same vicinity.
The data reported here also shed new light on our previ-
ous observations concerning the antiinflammatory effect of
IL-12 in endotoxin-induced uveitis, an acute model of an-
terior uveitis that is immune mediated, but not antigen spe-
cific (64). In that study, direct intraocular injection of IL-12
was able to reduce the number of inflammatory cells infil-
trating the anterior chamber, an effect that was accompa-
nied by elevated titers of IFN-g in the aqueous humor. In
view of the data reported here, we propose that this reduc-
tion in inflammatory cells could have been caused by their
elimination through apoptosis.
The present results appear to differ from those reported
in several other models of autoimmunity. Whether admin-
istered in vitro or in vivo, IL-12 accelerated the onset, and
increased the incidence and severity of disease in the EAE
and in the collagen-induced arthritis (CIA) models, as well
as in the nonobese diabetic (NOD) mouse (43–46). How-
ever, other investigators reported amelioration of CIA in
mice by continuous administration of high-dose IL-12, and
some IL-12 treatment regimens ameliorated diabetes in
NOD mice (65–67). Our results offer to reconcile the ap-
parent contradiction between enhancing and protective ef-
fects of IL-12 in the same model. Although the protective
effect of high-dose IL-12 in the CIA model (which is
strongly dependent on humoral immunity) was felt by the
authors to be due to an effect on antibody isotypes rather
than inhibition of cellular responses (65), it is interesting to
note that this study used CFA, itself a strong IL-12 inducer,
in the immunization protocol. In contrast, none of the
studies that documented enhancement of disease used an
induction regimen incorporating CFA. Similarly, induction
of EAU in the present study was achieved by immunization
using both CFA and PTX as adjuvants. However, under
conditions of adoptive transfer IL-12 increases the pathoge-
nicity of retinal antigen–specific T cells (24, 68). Therefore
it could tbe hypothesized that the immunization protocol
for induction of EAU already generates a maximum Th1
response, which cannot be further upregulated by the ex-
ogenous IL-12 treatment, resulting in an effective IL-12
overdose. This interpretation is also in line with the finding
that we did not obtain exacerbation of EAU at any of the
IL-12 doses. Our data thus argue that an excess of IL-12
during priming can abort a Th1-mediated autoimmune
disease instead of bringing about its exacerbation, by trig-
gering a negative feedback loop.
In summary, the present study shows that administration
of the Th1-inducing cytokine IL-12 protects from a Th1-
dependent autoimmune disease, EAU, and inhibits across
the board the cellular and humoral immune responses to
the uveitogenic antigen. The mechanism of this phenome-
non involves hyperinduction of systemic IFN-g, causing
upregulation of iNOS and production of NO, which pro-228 IL-12 Protects from Experimental Autoimmune Uveitis
tects at least in part by triggering Bcl-2 controlled apoptotic
deletion of antigen-specific cells at a critical time point dur-
ing antigen priming. We conclude that protection from
EAU by IL-12 is secondary to a curtailment in generation
of uveitogenic effector T cells. The present study also pro-
poses a likely explanation for the well-documented protec-
tive effects of systemic IFN-g in Th1-dependent autoim-
munity.
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